NEW YORK – Postmenopausal, early-stage breast cancer patients whose disease has spread to the lymph nodes may not derive additional benefit from adjuvant chemotherapy if they have an Oncotype DX score of 25 or lower, according to new results from an ongoing clinical trial.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.